287 results
Page 3 of 15
8-K
EX-99.1
b3efiwl p8
5 Jul 23
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
q70i7d7
15 Jun 23
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
8:00am
8-K
EX-99.1
l2qonweoj9w
7 Jun 23
VBI Vaccines Announces Poster Presentation at EASL 2023
8:00am
8-K
EX-99.1
1u8p9re2uz6
15 May 23
VBI Vaccines Reports First Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
pus6qfuvlx0lbifo47ga
25 Apr 23
VBI Vaccines Appoints Vaughn Himes to Board of Directors
8:00am
8-K
EX-99.1
lqj3hh
4 Apr 23
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
8:00am
8-K
EX-99.1
y156zmd
8 Dec 22
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
8:00am
8-K
EX-99.1
hjfkl3
6 Dec 22
Entry into a Material Definitive Agreement
9:25am
8-K
EX-99.1
03q2em
22 Nov 22
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
8:00am
8-K
EX-99.1
z4f 9srkhhrpbv
10 Nov 22
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
orkkt9mq
12 Oct 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
o3t8iqku3azjkp1o
29 Sep 22
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
8:00am
8-K
EX-99.1
arcfe3x1zg 23
21 Sep 22
Regulation FD Disclosure
8:10am
8-K
EX-10.1
c3df6emyz 2dtw3i8
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
42hb38wf m4
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
yecgks
8 Sep 22
Regulation FD Disclosure
6:10am